Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Pharmaceutical Business ReviewAuvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication.NeuroscienceRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: LEO Pharma to acquire gene therapy company ReplayNext: FDA’s ODAC delivers one loss, one win for AstraZeneca Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
